Lupin Pharma

Business

Lupin Limited Achieves Milestone in Biosimilar Development with LUBT010

Lupin Limited has announced a major breakthrough in biosimilars with the successful completion of a global Phase 3 clinical trial for LUBT010, its biosimilar to Lucentis. The study confirmed that LUBT010 meets its primary goal of demonstrating equivalent therapeutic efficacy in improving visual acuity for patients with wet age-related macular degeneration (AMD). The results indicated that LUBT010 offers comparable safety…